These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 9777103)

  • 21. Synthesis and biological evaluation of novel 2,4,6-triazine derivatives as antimicrobial agents.
    Gavade SN; Markad VL; Kodam KM; Shingare MS; Mane DV
    Bioorg Med Chem Lett; 2012 Aug; 22(15):5075-7. PubMed ID: 22742908
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antimicrobial activity of nicotine against a spectrum of bacterial and fungal pathogens.
    Pavia CS; Pierre A; Nowakowski J
    J Med Microbiol; 2000 Jul; 49(7):675-6. PubMed ID: 10882095
    [No Abstract]   [Full Text] [Related]  

  • 23. In vitro antibacterial activities of AF 3013, the active metabolite of prulifloxacin, against nosocomial and community Italian isolates.
    Montanari MP; Mingoia M; Varaldo PE
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3616-22. PubMed ID: 11709353
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hansch analysis of veratric acid derivatives as antimicrobial agents.
    Narasimhan B; Ohlan S; Ohlan R; Judge V; Narang R
    Eur J Med Chem; 2009 Feb; 44(2):689-700. PubMed ID: 18597896
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative bactericidal activity of fluoroquinolones against clinical isolates resistant to fluoroquinolones.
    Drago L; De Vecchi E; Nicola L; Valli M; Marchetti F; Gismondo MR
    J Chemother; 2003 Apr; 15(2):118-23. PubMed ID: 12797386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms.
    Almer LS; Hoffrage JB; Keller EL; Flamm RK; Shortridge VD
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2771-7. PubMed ID: 15215148
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis of new (4-alkylamino-4'-fluoro)-diphenyl sulphones with potential biological activity.
    de Sousa Júnior PT; Miller J; Giesbrecht AM
    An Acad Bras Cienc; 1996; 68(2):161-4. PubMed ID: 9113300
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program.
    Jones RN; Pfaller MA
    Clin Infect Dis; 2000 Aug; 31 Suppl 2():S16-23. PubMed ID: 10984323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis of a novel class of some 1,3,4-oxadiazole derivatives as antimicrobial agents.
    Chikhalia KH; Vashi DB; Patel MJ
    J Enzyme Inhib Med Chem; 2009 Jun; 24(3):617-22. PubMed ID: 18642158
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and antibacterial activity of new fluoroquinolones containing a substituted N-(phenethyl)piperazine moiety.
    Foroumadi A; Ghodsi S; Emami S; Najjari S; Samadi N; Faramarzi MA; Beikmohammadi L; Shirazi FH; Shafiee A
    Bioorg Med Chem Lett; 2006 Jul; 16(13):3499-503. PubMed ID: 16644219
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antimicrobial activity of some heterocyclic derivatives of 1-methyl-1-nitroethyl sulphides.
    Ghannoum MA; Bowman WR; Valmas M
    Microbios; 1985; 42(171S):211-23. PubMed ID: 4033459
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Efflux pumps of gram-positive bacteria and resistance to fluoroquionolones].
    Egorov AM; Sazykin IuO
    Antibiot Khimioter; 2001; 46(8):3-5. PubMed ID: 11871317
    [No Abstract]   [Full Text] [Related]  

  • 33. Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria.
    Poole K
    Antimicrob Agents Chemother; 2000 Sep; 44(9):2233-41. PubMed ID: 10952561
    [No Abstract]   [Full Text] [Related]  

  • 34. Efflux-mediated resistance to fluoroquinolones in gram-positive bacteria and the mycobacteria.
    Poole K
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2595-9. PubMed ID: 10991829
    [No Abstract]   [Full Text] [Related]  

  • 35. Antibacterial activity and pharmacokinetics of four new 7-azetidinyl fluoroquinolones.
    Coll R; Gargallo-Viola D; Tudela E; Xicota MA; Llovera S; Guinea J
    Antimicrob Agents Chemother; 1996 Jan; 40(1):274-7. PubMed ID: 8787924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disposable antimicrobial and sporicidal privacy curtains: Cost benefit of hanging longer.
    Kotsanas D; Gillespie E
    Am J Infect Control; 2016 Jul; 44(7):854-5. PubMed ID: 26922893
    [No Abstract]   [Full Text] [Related]  

  • 37. [Pharmacokinetic interaction of fluoroquinolones and other drugs].
    Iakovlev VP
    Antibiot Khimioter; 1998; 43(7):36-44. PubMed ID: 9727166
    [No Abstract]   [Full Text] [Related]  

  • 38. Fluoroquinolones: considerations for future use.
    Congeni BL; Thomson RB
    Pediatr Infect Dis J; 2002 Apr; 21(4):345-6. PubMed ID: 12075768
    [No Abstract]   [Full Text] [Related]  

  • 39. Concomitant administration of drugs known to decrease the systemic availability of gatifloxacin.
    Bowes J; Graffunder EM; Lomaestro B; Venezia RA
    Pharmacotherapy; 2002 Jun; 22(6):800-1. PubMed ID: 12066975
    [No Abstract]   [Full Text] [Related]  

  • 40. Intravenous-to-oral switch in antimicrobial therapy: clinical pharmacology considerations and perspectives.
    Srinivas NR
    Future Microbiol; 2017 Aug; 12():847-851. PubMed ID: 28685614
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.